Dr. Mark Miller joined DCP's Chemopreventive Agent Development Research Group from the Wake Forest School of Medicine, where he was a Professor in the Department of Cancer Biology and Director of Graduate Studies. Prior to that, he was an Assistant Professor in the Department of Pathology at the University of Tennessee in Knoxville. He worked for NCI as a Senior Staff Fellow at the Frederick Cancer Research Facility in the Laboratory of Comparative Carcinogenesis. After earning his Ph.D. in Pharmacology at Columbia University, he trained as a postdoctoral fellow at the Massachusetts Institute of Technology.
His research interests have focused on the pathogenesis of pulmonary cancers; transplacental carcinogenesis; the molecular mechanisms of cancer and chemoprevention processes; gene/environmental interactions in determining individual susceptibility to lung and breast cancer; and the effects of chemical and physical carcinogens on the regulation of gene expression.